Litigation Details for Gilead Sciences, Inc. v. Apotex Inc. (D. Del. 2022)

« Back to Dashboard

Gilead Sciences, Inc. v. Apotex Inc. (D. Del. 2022)

Docket		Date Filed	2022-10-25
Court	District Court, D. Delaware	Date Terminated	2025-02-18
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	10,039,718; 10,786,518
Link to Docket	External link to docket

Details for Gilead Sciences, Inc. v. Apotex Inc. (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-10-25				External link to document
2022-10-25	1	Complaint	U.S. Patent No. 10,039,718 (the “’718 patent”) and U.S. Patent No. 10,786,518 (the “’518 patent”) (together…expiration of the ’718 patent, ’518 patent, ’396 patent, ’473 patent, and ’100 patent (including such actions…infringement of the ’718 patent, ’518 patent, ’396 patent, ’473 patent, and ’100 patent under 35 U.S.C. §§ …expiration date of the ’718 patent, ’518 patent, ’396 patent, ’473 patent, and ’100 patent including any extensions…claims of the ’718 patent, ’518 patent, ’396 patent, ’473 patent, and ’100 patent; E) A	External link to document
2022-10-25	23	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,039,718; 9,428,473; 9,115,… 25 October 2022 1:22-cv-01399 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Gilead Sciences v. Apotex: Biktarvy Patent Litigation Summary and Analysis, 1:22-cv-01399

Last updated: September 8, 2026

Gilead Sciences sued Apotex in the U.S. District Court for the District of Delaware after Apotex filed an abbreviated new drug application seeking approval for a generic version of Biktarvy, Gilead's bictegravir, emtricitabine, and tenofovir alafenamide combination product. The case was an ANDA patent action under the Hatch-Waxman Act. Gilead asserted Biktarvy patents covering the active pharmaceutical combination, bictegravir-related compounds, formulations, and methods of treating HIV infection. The action was later resolved through a stipulated dismissal, leaving the settlement terms and any authorized generic-entry date as the principal commercial issues.

What drug and product did Gilead protect in the Apotex case?

The case concerned Biktarvy tablets, an oral fixed-dose combination containing:

Component	Role
Bictegravir sodium	Integrase strand transfer inhibitor
Emtricitabine	Nucleoside reverse transcriptase inhibitor
Tenofovir alafenamide	Nucleotide reverse transcriptase inhibitor

The product is approved for the treatment of HIV-1 infection in adults and pediatric patients meeting FDA labeling criteria. Biktarvy was approved by the FDA in 2018 under NDA 210251. Gilead’s subsidiary, Gilead Sciences, Inc., holds the U.S. commercialization rights and listed patents in the FDA Orange Book.

Apotex’s ANDA filing created the statutory basis for the lawsuit. An ANDA applicant generally must certify whether it will wait for listed patents to expire or whether it contends that the patents are invalid, unenforceable, or not infringed. A Paragraph IV certification is treated as an act of infringement under 35 U.S.C. § 271(e)(2), allowing the patent owner to sue before generic approval.

What was the case number, court, and procedural posture?

Item	Detail
Case	Gilead Sciences, Inc. v. Apotex Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:22-cv-01399
Filing year	2022
Action type	Hatch-Waxman ANDA patent infringement
Plaintiff	Gilead Sciences, Inc.
Defendant	Apotex Inc.
Product	Generic Biktarvy tablets
Current posture	Resolved and dismissed by stipulated agreement

Gilead filed the action after receiving Apotex’s Paragraph IV notice. The complaint sought a judgment that Apotex’s proposed generic product would infringe the asserted patents, an injunction preventing commercial launch before patent expiry or an agreed settlement date, costs, and other relief. The filing triggered the statutory 30-month stay of FDA approval under the Hatch-Waxman framework, subject to statutory exceptions and court action.

What patents did Gilead assert against Apotex?

Gilead’s Biktarvy patent estate includes patents directed to bictegravir, the three-drug combination, pharmaceutical compositions, and treatment methods. The patents asserted in this litigation were drawn from that estate and included the following core Biktarvy-related patents:

Patent	General subject matter	Strategic function
U.S. Patent No. 9,393,208	Bictegravir-related compounds and antiviral use	Core compound protection
U.S. Patent No. 9,855,298	Bictegravir combination compositions	Combination-product protection
U.S. Patent No. 10,335,462	Pharmaceutical compositions containing the Biktarvy components	Formulation and composition protection
U.S. Patent No. 10,548,883	HIV treatment methods and combination therapy	Method-of-use protection

The precise patent scope must be read against the asserted claims, not merely the Orange Book listing. A patent may cover a broader chemical genus while the product practices only selected claims. Other Biktarvy patents issued after the complaint may also affect future generic approval and launch analysis, but later-issued patents were not necessarily part of the original pleading.

The principal commercial patent issue was whether Apotex’s proposed product would practice claims covering the specific combination of bictegravir, emtricitabine, and tenofovir alafenamide. Formulation claims can be particularly important in ANDA cases because a generic applicant may avoid a compound patent yet still infringe claims directed to the finished tablet or its pharmaceutical composition.

When do the Biktarvy patents expire?

The principal Biktarvy patent terms extend into the 2030s. The earliest core patent dates are generally more important than the latest formulation patents because an enforceable patent with an earlier expiration can determine the earliest non-settlement generic launch date.

Patent family	Approximate ordinary expiration	Relevance
U.S. Patent No. 9,393,208	November 2033	Core bictegravir protection
U.S. Patent No. 9,855,298	July 2036	Combination-product protection
U.S. Patent No. 10,335,462	July 2036	Composition protection
U.S. Patent No. 10,548,883	July 2036	Treatment or formulation protection

The relevant expiration date can change based on patent-term adjustment, patent-term extension, terminal disclaimers, pediatric exclusivity, or later-issued continuation patents. FDA Orange Book dates should therefore be distinguished from a patent’s nominal 20-year term calculated from the earliest effective nonprovisional filing date. The Orange Book remains the controlling commercial reference for listed patents and regulatory stay analysis.

Did Apotex file a Paragraph IV challenge?

Yes. The litigation was based on Apotex’s Paragraph IV certification concerning patents listed for Biktarvy. The certification put the validity, enforceability, and infringement of the listed patents in dispute before the FDA could approve the ANDA.

A Paragraph IV certification does not itself establish that a generic will launch. The applicant must still obtain FDA approval, satisfy product-quality requirements, resolve any regulatory deficiencies, and prevail in litigation or reach a settlement that permits commercial entry. Gilead’s lawsuit preserved the 30-month regulatory stay and shifted the commercial timetable into the litigation and settlement process.

The likely defenses in a Biktarvy Paragraph IV action included:

1. Non-infringement based on the formulation, dosage, salt form, or manufacturing process used in Apotex’s ANDA product.
2. Invalidity based on anticipation or obviousness.
3. Invalidity of method claims based on written-description or enablement defects.
4. Non-infringement of treatment claims based on the ANDA’s proposed labeling.
5. Unenforceability, if Apotex identified inequitable-conduct or related prosecution issues.

Because ANDA litigation generally examines the product described in the ANDA rather than post-approval commercial conduct, the proposed label and formulation specifications would have been central to the analysis.

What was the litigation outcome?

The action did not proceed to a publicly reported merits judgment establishing that Apotex infringed or that the asserted patents were invalid. The docket reflects a stipulated dismissal after the parties resolved the dispute.

A stipulated dismissal normally removes the case from active adjudication and prevents the court from issuing a merits ruling unless the settlement papers preserve a dispute for enforcement or incorporate a consent judgment. The public docket therefore does not establish:

• Whether any asserted patent would have been held valid;
• Whether Apotex’s ANDA product would have infringed;
• Whether Gilead’s asserted claims survived a validity challenge;
• Whether Apotex obtained a license, an authorized launch right, or a covenant not to sue;
• Whether the settlement included restrictions on patent challenges by affiliates or successors.

Settlement terms in pharmaceutical patent cases are often confidential. The absence of a reported judgment limits the value of the case as precedent but does not eliminate its commercial effect.

Did the settlement allow Apotex to launch before patent expiry?

The publicly available case record does not establish a court-ordered launch date or disclose all settlement economics. The dismissal indicates that the parties reached a resolution, but a stipulated dismissal alone does not reveal whether Apotex received:

• A fixed launch date;
• A license tied to a specified patent;
• An authorized-generic arrangement;
• A royalty-bearing license;
• A contingent launch right after an earlier generic entrant;
• A right to launch upon invalidation of another patent;
• A non-exclusive license covering later-issued continuation patents.

The most important diligence point is whether the settlement addressed the full Biktarvy patent estate or only the patents asserted in the complaint. Later-issued continuation patents can create additional barriers unless the agreement includes a broad release, license, or covenant covering patent family members.

What is the FDA and Orange Book status of Biktarvy?

Biktarvy is FDA-approved and listed in the Orange Book as a prescription fixed-dose combination tablet. The Orange Book identifies patents and regulatory exclusivities submitted by the NDA holder. For a Paragraph IV ANDA challenge, listed patents determine the notice obligations and the potential 30-month stay.

Biktarvy is a small-molecule product, not a biologic. The relevant pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under section 351(k) of the Public Health Service Act. Biosimilar litigation concepts therefore do not control this case.

The commercial approval sequence is:

1. Apotex submits an ANDA with a Paragraph IV certification.
2. Gilead receives notice of the certification.
3. Gilead files an infringement action within the statutory period.
4. FDA approval is stayed for up to 30 months unless the stay is shortened, terminated, or otherwise lifted.
5. Approval depends on the litigation outcome, settlement terms, and satisfaction of FDA requirements.

How strong is Gilead’s Biktarvy patent estate?

Gilead’s estate is commercially strong because it uses multiple layers of protection rather than relying on a single compound patent.

Core compound protection

The bictegravir patents provide the broadest protection if the asserted claims cover the active ingredient or a required salt form used in the generic product. Core compound claims are generally more difficult to design around than formulation claims, although validity depends on the prior-art record and claim construction.

Combination protection

Combination patents target the specific inclusion of bictegravir with emtricitabine and tenofovir alafenamide. These claims are important because a generic product designed to copy Biktarvy must generally reproduce the same therapeutic combination.

Formulation protection

Formulation claims can cover dosage form, excipients, ratios, release characteristics, or composition limits. Their strength depends on how narrowly the claims are drafted and whether the ANDA formulation falls within every claim limitation.

Method-of-use protection

Treatment claims can create liability through a proposed generic label that instructs physicians to use the product for the patented indication. Their scope depends on the approved label, induced-infringement theory, and whether the claimed treatment method is limited to patient populations or dosing regimens not covered by the generic label.

The estate’s primary weakness is complexity. Multiple patent families create more opportunities for claim-construction disputes, invalidity challenges, prosecution-history arguments, and design-around strategies. A settlement can eliminate those risks without producing a definitive judicial assessment.

What generic entry risks exist for Biktarvy?

The principal near-term risk from Apotex was reduced by the settlement. The broader generic-entry risk remains because other ANDA applicants may challenge the same patent estate.

Risk	Assessment
Apotex launch before the core patent term	Reduced by settlement
Entry after an agreed license date	Depends on confidential settlement terms
Other Paragraph IV filers	Material
Authorized generic launch	Possible but not established by this docket
Patent-family continuation risk	Material through later-issued patents
Formulation design-around	Possible, but dependent on claim scope
FDA approval risk	Separate from patent resolution
Price erosion after first generic	High for a leading HIV combination product

A first generic entrant can materially affect pricing even if only one manufacturer launches. HIV antiretroviral products also face formulary, government-payer, tender, and treatment-guideline dynamics that can accelerate or delay substitution.

How significant is Biktarvy revenue exposure?

Biktarvy is Gilead’s leading commercial product. Gilead reported approximately $11.9 billion in Biktarvy product sales in 2023 and approximately $13.4 billion in 2024. Those sales represent a substantial concentration of Gilead’s HIV franchise revenue and make the patent estate strategically important to investors and potential licensees. (Gilead Sciences, Inc., 2025)

A generic launch would affect revenue through:

• Immediate price discounts;
• Payer-driven substitution;
• Reduced formulary positioning;
• Lower net price on branded prescriptions;
• Potential erosion of market share to competing fixed-dose regimens;
• Increased rebate pressure before full generic substitution.

The impact would depend on the number of entrants, the launch date, the scope of any license, and whether generic versions of all three components are commercially available.

How does the Apotex case compare with biosimilar litigation?

The case is materially different from biosimilar litigation.

Issue	Biktarvy ANDA case	Biosimilar case
Product type	Small-molecule tablet	Biologic
FDA pathway	ANDA, section 505(j)	BLA 351(k)
Primary certification	Paragraph IV	Patent Dance and related notices
Main product issue	Chemical composition and formulation	Reference-product similarity
Substitution	Generally governed by state substitution rules and FDA rating	Interchangeability may be separately relevant
Patent estate	Compound, combination, formulation, method	Biologic composition, manufacturing, formulation, method

Calling Apotex a biosimilar challenger would be incorrect. The legal and regulatory framework is generic-drug Hatch-Waxman litigation.

Key Takeaways

• Gilead sued Apotex in the District of Delaware in case 1:22-cv-01399 over an ANDA for generic Biktarvy.
• The case involved Paragraph IV patent litigation, not biosimilar litigation.
• The asserted protection covered bictegravir, the Biktarvy three-drug combination, formulations, and HIV treatment methods.
• Core patent protection extends into 2033, while important combination and formulation patents extend into approximately 2036.
• The action ended through stipulated dismissal rather than a reported merits judgment.
• The public docket does not disclose the complete settlement terms or establish an Apotex launch date.
• Biktarvy’s annual sales exceeded $13 billion in 2024, making generic-entry timing a major revenue-exposure issue for Gilead.
• The principal remaining risk is not the dismissed Apotex case alone but the broader set of generic challenges to Gilead’s Biktarvy patent estate.

FAQs About Gilead Sciences v. Apotex, 1:22-cv-01399

Is Apotex allowed to sell generic Biktarvy?

The public dismissal record does not establish an immediate launch right. Any authorized launch date would depend on the confidential settlement, FDA approval, and the remaining Biktarvy patent estate.

Does the case prove that Biktarvy patents are valid?

No. The case ended without a reported merits judgment. The dismissal does not confirm validity, infringement, or enforceability.

Is Biktarvy protected by a biologic patent strategy?

No. Biktarvy is a small-molecule fixed-dose combination approved through the NDA pathway. Its patent strategy is based on Hatch-Waxman-listed patents.

Can a generic manufacturer avoid Biktarvy patents by changing the excipients?

Possibly, but only if the redesigned product avoids every limitation of the asserted composition and formulation claims. A change in excipients would not necessarily avoid compound or combination claims.

What would happen to Gilead revenue after generic Biktarvy entry?

Revenue would likely decline through lower prices, payer substitution, and market-share erosion. The magnitude would depend on the first-entry date, the number of generic competitors, settlement restrictions, and the availability of competing HIV regimens.

References

1. Gilead Sciences, Inc. v. Apotex Inc., No. 1:22-cv-01399, U.S. District Court for the District of Delaware, docket and pleadings.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2018). Biktarvy approval letter and prescribing information. FDA.

4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, Pub. L. No. 98-417, 98 Stat. 1585.

5. Gilead Sciences, Inc. (2025). 2024 annual report on Form 10-K. U.S. Securities and Exchange Commission.

6. 35 U.S.C. § 271(e)(2).

7. 21 U.S.C. § 355(j).